Quantcast

Latest Exosome Stories

2014-06-25 12:29:13

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19(th), is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at...

2014-06-10 08:30:28

POINT ROBERTS, Wash. and NEW YORK, June 10, 2014 /PRNewswire/ -- Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a Q&A interview with Mr. James A. Joyce ,Chairman and CEO of Aethlon Medical, Inc. (OTCBB: AEMD). Mr. Joyce shares insight into the emerging Immuno-Oncology market and the opportunity it represents. Q: Investorideas.com How did Aethlon Medical become involved in cancer research? A: James A. Joyce,...

2014-06-03 08:32:14

NEW YORK, June 3, 2014 /PRNewswire/ -- Exosome Diagnostics, a leading developer of non-invasive, biofluid-based molecular diagnostics, today announced that Vincent J. O'Neill, M.D., has been appointed as its chief medical officer. Dr. O'Neill has extensive experience in clinical trial design, regulatory issues, and personalized medicine, most recently as global head Personalized of Medicine and Companion Diagnostics at Sanofi. At Sanofi, he defined the personalized medicine...

2014-05-28 08:31:28

NEW YORK, May 28, 2014 /PRNewswire/ -- Exosome Diagnostics, a leading developer of non-invasive, biofluid-based molecular diagnostics, today announced that William J. Kelly has been appointed as its chief financial officer, effective May 27, 2014. Mr. Kelly, 43, has over 20 years of financial management experience, including the past 13 years leading growing, international, publicly traded life science companies. For the past six years, Mr. Kelly worked at RepliGen Corporation,...

2014-05-14 08:31:42

SAN DIEGO, May 14, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b The discovery that our Hemopurifer® captures tumor-secreted exosomes provides hope for a new therapeutic paradigm to augment cancer care. Yes, the same Hemopurifier® we are preparing to advance in a forthcoming FDA approved infectious disease study. In my last CEO note, I...

2014-04-22 08:33:24

SAN DIEGO, April 22, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b When we initiated our first exosome research program, the medical community generally viewed these particles as nothing more than cellular debris with no biological function. In contrast, we believed that exosomes, also known as microvesicles or extracellular vesicles,...

2014-03-11 08:29:02

NEW YORK, March 11, 2014 /PRNewswire/ -- Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas. Key Points: -- Co-leading the financing were new investors QIAGEN and Arcus Ventures --...

2014-03-05 08:29:37

Discoveries Could Have Implications in the Diagnosis, Monitoring and Treatment of Alzheimer's Disease, Chronic Traumatic Encephalopathy and Traumatic Brain Injury SAN DIEGO, March 5, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications...

2014-02-26 08:29:00

SAN DIEGO, Feb. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in principle with DaVita Clinical Research® (DCR) to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class therapeutic...

2014-02-19 23:31:12

Colleen’s Dream Foundation has granted $11,000 to Memorial Sloan-Kettering Cancer Center to help fund ovarian cancer research being conducted by Dr. Vance Broach, according to Colleen’s Dream Foundation President Billy Cundiff. Phoenix, AZ (PRWEB) February 19, 2014 With the help of ovarian cancer survivor Jill Pall and NFL kicker Ryan Quigley, Colleen’s Dream Foundation has granted $11,000, to Memorial Sloan-Kettering Cancer Center to help fund ovarian cancer research being...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related